Highlighting clinical needs in Clostridium difficile infection: the views of European healthcare professionals at the front line.

Astellas Pharma EMEA initiated and fully supported the consensus project including the selection of the initial faculty of experts, who were able to cover the broad aspects of CDI management. Astellas Pharma EMEA paid the expert group an honorarium and travel expenses. Astellas Pharma EMEA commissioned Triducive Ltd to facilitate the project and analyse the responses to the consensus statements, in line with the Delphi methodology, and supported the authors in producing the manuscript. Astellas Pharma EMEA provided editorial assistance for the final manuscript by way of a factual accuracy check only. H. Seifert reports grants or research support from the Bundesministerium fu¨r Bildung und Forschung (BMBF), Germany, the German Center for Infection Research, Basilea, Novartis and Pfizer; has been a consultant for Astellas, AstraZeneca, Basilea, Cubist, Novartis, Pfizer, and The Medicines Company; and has received payments for lectures from MSD, Novartis, and Pfizer. A. Stallmach reports honoraria for participating in scientific advisory boards organized by Astellas. All of his activities and contracts are in conformity with the ‘FSAKodex Fachkreise’ (voluntary self-monitoring code for expert consultants to the pharmaceutical industry), have been checked by the Medicolegal Department of the University Hospital Jena, and have been approved by the directorate of the Faculty of Medicine. S. Goldenberg reports consulting fees, lecture fees, and research grants from Astellas. V. Anttila reports research support from MSD, Pfizer, GSK, and Astellas, consulting fees from MSD, and lecture fees from MSD, Pfizer, and Astellas. D. Jenkins reports speaker fees and advisory board fees from Astellas and is a director of Healthcare Infection Prevention Ltd. T. Galperine reports advisory board fees from Astellas. N. Petrosillo reports speaker’s fees from MSD, Novartis, Astellas, Gilead, Pfizer, advisory board fees from Carefusion, Johnson & Johnson, Ac